U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
The award recognizes and supports promising women scientists
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Expanding the Applied Biosystems portfolio with the latest generation of innovative, mid-throughput genetic analyzers
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Subscribe To Our Newsletter & Stay Updated
